Home The Word Brain	My Amedeo FAQ Privacy About
	As of October 2023, Amedeo had 12,263 active subscribers

Prostate Cancer

Free Subscription 20.11.2023 1 BMC Urol 3 Br J Cancer 2 Eur Urol 2 Int J Cancer 1 J Clin Oncol 1 J Natl Cancer Inst 1 J Surg Oncol 2 J Urol 1 Nat Rev Urol 1 PLoS One 2 Prostate 1 Radiology 1 Urology

Retrieve available abstracts of this week’s articles: HTML format

Single Articles

BMC Urol

1. BEJRANANDA T, Pliensiri P
   Prediction of biochemical recurrence after laparoscopic radical prostatectomy.
   BMC Urol. 2023;23:183.
   PubMed         Abstract available
   
   

   
   Br J Cancer

2. SHEN J, Chowdhury S, Agarwal N, Karsh LI, et al
   Apalutamide efficacy, safety and wellbeing in older patients with advanced prostate cancer from Phase 3 randomised clinical studies TITAN and SPARTAN.
   Br J Cancer. 2023 Nov 11. doi: 10.1038/s41416-023-02492.
   PubMed         Abstract available
   
   
3. AHMAD AS, Offman J, Delon C, North BV, et al
   Years of life lost due to cancer in the United Kingdom from 1988 to 2017.
   Br J Cancer. 2023;129:1558-1568.
   PubMed         Abstract available
   
   
4. CAMERON JM, Sala A, Antoniou G, Brennan PM, et al
   A spectroscopic liquid biopsy for the earlier detection of multiple cancer types.
   Br J Cancer. 2023;129:1658-1666.
   PubMed         Abstract available
   
   

   
   Eur Urol

5. MOORE CM, Albertsen P
   When Is It Too Early To Start Prostate Cancer Screening? Reflections on the PROBASE Study Using Magnetic Resonance Imaging for Men Aged 45 Yr with Elevated Prostate-specific Antigen.
   Eur Urol. 2023 Nov 13:S0302-2838(23)03212-8. doi: 10.1016/j.eururo.2023.
   PubMed        
   
   
6. HAMDY FC, Donovan JL
   Reply to Greg Shaw, John D. Kelly, and Monique J. Roobol's Letter to the Editor re: Freddie C. Hamdy, Jenny L. Donovan, J. Athene Lane, et al. Fifteen-Year Outcomes After Monitoring, Surgery, or Radiotherapy for Prostate Cancer. N Engl J Med 2023;388:
   Eur Urol. 2023 Nov 8:S0302-2838(23)03218-9. doi: 10.1016/j.eururo.2023.
   PubMed        
   
   

   
   Int J Cancer

7. RANGANATHAN S, Dee EC, Debnath N, Patel TA, et al
   Access and barriers to genomic classifiers for breast cancer and prostate cancer in India.
   Int J Cancer. 2023 Nov 14. doi: 10.1002/ijc.34784.
   PubMed         Abstract available
   
   
8. ZAHED H, Feng X, Sheikh M, Bray F, et al
   Age at diagnosis for lung, colon, breast and prostate cancers: An international comparative study.
   Int J Cancer. 2024;154:28-40.
   PubMed         Abstract available
   
   

   
   J Clin Oncol

9. MATEO J, de Bono JS, Fizazi K, Saad F, et al
   Olaparib for the Treatment of Patients With Metastatic Castration-Resistant Prostate Cancer and Alterations in BRCA1 and/or BRCA2 in the PROfound Trial.
   J Clin Oncol. 2023 Nov 14:JCO2300339. doi: 10.1200/JCO.23.00339.
   PubMed         Abstract available
   
   

   
   J Natl Cancer Inst

10. COOPERBERG MR
    Can early prostate cancer screening help address mortality disparities among Black men?
    J Natl Cancer Inst. 2023 Nov 10:djad217. doi: 10.1093.
    PubMed        
    
    

    
    J Surg Oncol

11. HAYASHI MC, Sarri AJ, Pereira PASV, Rocha MM, et al
    Ergonomic risk assessment of surgeon's position during radical prostatectomy: Laparoscopic versus robotic approach.
    J Surg Oncol. 2023;128:1453-1458.
    PubMed         Abstract available
    
    

    
    J Urol

12. CHEN Y, Liang Z, Yan W
    Biopsy Assessment of Oncologic Control 3 Years Following Primary Partial Gland Cryoablation: A Prospective Cohort Study of Men With Intermediate-Risk Prostate Cancer. Letter.
    J Urol. 2023 Nov 14:101097JU0000000000003781. doi: 10.1097/JU.0000000000003781.
    PubMed        
    
    
13. LEPOR H
    Biopsy Assessment of Oncologic Control 3 Years Following Primary Partial Gland Cryoablation: A Prospective Cohort Study of Men With Intermediate-Risk Prostate Cancer. Reply.
    J Urol. 2023 Nov 15:101097JU0000000000003782. doi: 10.1097/JU.0000000000003782.
    PubMed        
    
    

    
    Nat Rev Urol

14. GONG J, Kim DM, Freeman MR, Kim H, et al
    Genetic and biological drivers of prostate cancer disparities in Black men.
    Nat Rev Urol. 2023 Nov 14. doi: 10.1038/s41585-023-00828.
    PubMed         Abstract available
    
    

    
    PLoS One

15. CAMERON JK, Chandrasiri U, Millar J, Aitken JF, et al
    Disease mapping: Geographic differences in population rates of interventional treatment for prostate cancer in Australia.
    PLoS One. 2023;18:e0293954.
    PubMed         Abstract available
    
    

    
    Prostate

16. AL SHAREEF Z, Al-Shahrabi R, Saheb Sharif-Askari F, AlDhmanie A, et al
    Incidence and risk factors of prostate cancer among the Northern and Eastern parts of the United Arab Emirates population.
    Prostate. 2023 Nov 15:e24637. doi: 10.1002/pros.24637.
    PubMed         Abstract available
    
    
17. PALLER CJ, Barata PC, Lorentz J, Appleman LJ, et al
    PROMISE Registry: A prostate cancer registry of outcomes and germline mutations for improved survival and treatment effectiveness.
    Prostate. 2023 Nov 14. doi: 10.1002/pros.24650.
    PubMed         Abstract available
    
    

    
    Radiology

18. TAKAHASHI T
    Prebiopsy Risk Calculators, Such as MRI and Prostate Cancer Screening, Are Early-phase Clinical Trials.
    Radiology. 2023;309:e231177.
    PubMed        
    
    

    
    Urology

19. STENSLAND KD, Caram ME, Herr DJ, Burns JA, et al
    National long-term survival estimates after radical prostatectomy for prostate cancer.
    Urology. 2023 Nov 9:S0090-4295(23)00987-1. doi: 10.1016/j.urology.2023.
    PubMed         Abstract available
    
    

Thank you for your interest in scientific medicine.

AMEDEO Prostate Cancer is free of charge.